EGFR and neoplasm: The reason is that the pemetrexed used in group q has an anti-tumor effect, but the therapeutic effect on NSCLC is not obvious, while the osimertinib used in group p has a targeted therapeutic effect on the patients with NSCLC with EGFR gene mutation.